Atea Pharmaceuticals Inc. (AVIR) Social Stream
Atea Pharmaceuticals Inc (AVIR) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Atea Pharmaceuticals Inc.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-12 | 5 | $20 | $14 | $16.666 | $6.99 | 138.43% |
| 2021-11-18 | 5 | $16 | $11 | $13.666 | $6.99 | 95.51% |
| 2021-12-15 | 4 | $16 | $11 | $13.666 | $6.99 | 95.51% |
| 2022-01-04 | 4 | $14 | $10 | $11.666 | $6.99 | 66.9% |
| 2022-01-06 | 4 | $11 | $7 | $9.333 | $6.99 | 33.52% |
| 2022-01-31 | 4 | $11 | $6 | $9 | $6.99 | 28.76% |
| 2022-02-15 | 4 | $10 | $6 | $8.666 | $6.99 | 23.98% |
| 2022-02-28 | 4 | $10 | $6 | $8.333 | $6.99 | 19.21% |
| 2022-03-07 | 4 | $9 | $6 | $7.666 | $6.99 | 9.67% |
The Trend in the Analyst Price Target
AVIR's average price target has moved down $41.33 over the prior 13 months.
Over the past 138 days, AVIR's average upside potential has been 37.91%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-18 | 5 | 16 | 11 | 13.666 | 8.62 | 58.54% |
| 2021-11-18 | 4 | 16 | 11 | 13.666 | 8.62 | 58.54% |
| 2022-01-04 | 4 | 14 | 10 | 11.666 | 8.62 | 35.34% |
| 2022-02-28 | 4 | 10 | 6 | 8.333 | 6.34 | 31.44% |
| 2022-03-07 | 4 | 9 | 6 | 7.666 | 5.89 | 30.15% |
AVIR Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.83 | 1 | 0 | 2 | 1 | 1 | 4 |
The Trend in the Broker Recommendations
AVIR's average broker recommendation rating improved by 0 over the prior 59 days.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- AVIR has a greater average analyst price target than 92.46% of all US stocks.
- AVIR has a greater number of analysts covering the stock than 161.51% of stocks in the mid market cap category.
- Atea Pharmaceuticals Inc's upside potential (average analyst target price relative to current price) is greater than 183.4% of Pharmaceutical Products stocks.
- In the context of Pharmaceutical Products stocks, Atea Pharmaceuticals Inc's variance in analysts' estimates is lower than -212.83% of them.
In the Pharmaceutical Products industry, AUPH, ATAI, and ASND are the three stocks most similar to Atea Pharmaceuticals Inc regarding the price target and analyst recommendation information presented here.
Is AVIR a Buy, Hold or Sell? See the POWR Ratings now!